NCT03953157View on ClinicalTrials.gov

Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

December 19, 2024

Study Completion Date

December 19, 2024

Conditions
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8ArthralgiaPostmenopausalPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions
DIETARY_SUPPLEMENT

Dietary Intervention

Receive dietary intervention

BEHAVIORAL

Exercise Intervention

Receive exercise intervention

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
lead

Jonsson Comprehensive Cancer Center

OTHER

NCT03953157 - Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors | Biotech Hunter | Biotech Hunter